Skip header and navigation

3 records – page 1 of 1.

Document Type
Rapid Review
Review Code
EOC062201v2 RR
Question Submitted
June 22, 2020
Date Completed
January 22, 2021
Status
5. Updated review
Research Team
EOC
chemotherapy and otherwise healthy individuals? (Update) Abbreviated Title: COVID-19 Chemotherapy Review ID
Document Type
Rapid Review
Review Code
EOC062201v2 RR
Question Submitted
June 22, 2020
Date Completed
January 22, 2021
Status
5. Updated review
Research Team
EOC
Updated Key Findings
Generally speaking, data indicate that adult cancer patients and those who have recently received or are receiving anti-cancer therapy are at a higher risk of severe outcomes and death resulting from COVID-19 compared to those without cancer. However, more data are beginning to elucidate the nuances of these risks depending on patient specific factors.
Limited data indicate that pediatric cancer patients are not at a high level of risk of severe outcomes from COVID-19.
Limited evidence indicates some differences in the course and severity of SARS-CoV-2 infection depending on the type of immunosuppressive therapy a patient receives.
Key Findings
Generally speaking, data indicate that adult cancer patients and those who have recently received or are receiving anti-cancer therapy are at a higher risk of severe outcomes and death resulting from COVID-19 compared to those without cancer.
Pediatric cancer populations may not be at the same level of risk as adult populations.
There is not enough evidence at this time to determine if there are differences in the course of SARS-CoV-2 infection in patients receiving chemotherapy vs. those who are not aside from outcomes and severity.
Category
Clinical Presentation
Subject
Chemotherapy
Cancer
Comorbidities
Natural History
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Vanstone, J; Groot, G; Miller, L; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 22; Document no.: EOC062201v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report)
Review History
EOC062201 RR: June 29, 2020
Related Documents
Documents
Less detail
Document Type
Table
Review Code
EOC062201v2 RR Table
Question Submitted
June 22, 2020
Date Completed
January 22, 2021
Status
5. Updated review
Research Team
EOC
course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? (Update
Document Type
Table
Review Code
EOC062201v2 RR Table
Question Submitted
June 22, 2020
Date Completed
January 22, 2021
Status
5. Updated review
Research Team
EOC
Category
Clinical Presentation
Subject
Chemotherapy
Cancer
Comorbidities
Natural History
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Vanstone, J; Groot, G; Miller, L; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 22; Document no.: EOC062201v2 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST table)
Review History
EOC062201 RR: June 29, 2020
Related Documents
Documents

EOC062201v2 RR Table

Download File
Less detail
Document Type
Evidence Search Report
Review Code
EOC062201v2-01 ESR
Question Submitted
June 22, 2020
Date Completed
January 4, 2021
Status
5. Updated review
Research Team
EOC
chemotherapy and otherwise healthy individuals? (Update) UNIQUE IDENTIFIER: EOC062201v2-01 ESR CONTEXT
Document Type
Evidence Search Report
Review Code
EOC062201v2-01 ESR
Question Submitted
June 22, 2020
Date Completed
January 4, 2021
Status
5. Updated review
Research Team
EOC
Category
Clinical Presentation
Subject
Comorbidities
Chemotherapy
Cancer
Natural History
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Miller, L.; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 4; Document no.: EOC062201v2 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 46 p. (CEST evidence search report)
Review History
EOC062201 RR: June 29, 2020
Related Documents
Documents

EOC062201v2-01 ESR

Read PDF Download PDF
Less detail